The Utility of I-123 Pretherapy Scan in I-131 Radioiodine Therapy for Thyroid Cancer
- 1 March 2012
- journal article
- research article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 22 (3), 304-309
- https://doi.org/10.1089/thy.2011.0203
Abstract
Background: There is a growing belief that a pretherapy scan yields little or no additional information that would impact on radioiodine ablation dosing. In addition, there is some concern regarding on the stunning effect of a pretherapy scan, especially when I-131 radioisotope is used for imaging. We hypothesized that a pretherapy scan provides invaluable information on the amount of thyroid remnant, sometimes indicating the need for two-step I-131 ablation. It may also detect unsuspected local lymph node involvement or distant metastases, indicating the requirement for a higher I-131 dose after thyroidectomy. The aim of this study was to evaluate how effective pretherapy scans are for guiding I-131 therapy planning and augmenting information provided in the pathology reports for thyroidectomy specimens. Methods: We reviewed 122 patients who underwent I-123 pretherapy scan and I-131 radioablation at Yale New Haven Hospital between January 2006 and August 2007. The percentage of neck uptake and whole-body images were acquired 24 hours following the administration of 51.8 MBq (1.4 mCi) of I-123 NaI. A 24-hour uptake of >3% was used as the cutoff to determine whether there was a greater than desired quantity of thyroid remnant, which would require a two-step treatment protocol. Furthermore, attention was paid to identifying cervical lymph nodes, which may not have presented themselves in the euthyroid state at the time of thyroidectomy. Additional clinical information provided by pretherapy scans was computed as percentages with 95% confidence intervals by using adjusted Wald intervals. Results: Overall, the pretherapy scans provided additional critical information in 25% of the cases (31/122; 95% CI: 18%–34%). For cases demonstrating >3% uptake with midline lymph nodes, the pretherapy scan provided additional information in 50% of the cases (8/16; 95% CI: 28%–72%). Conclusions: Our study demonstrated that I-123 pretherapy scans provide valuable information with regard to unsuspected lymph nodes or distant metastases, indicating the requirement for a significantly higher I-131 dose, and unexpected large thyroid remnants, suggesting the need for two-step ablation. We should take advantage of stimulated pretherapy scans and adjust the treatment dosing accordingly.Keywords
This publication has 25 references indexed in Scilit:
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- The Low Utility of Pretherapy Scans in Thyroid Cancer PatientsThyroid®, 2009
- Guidelines for radioiodine therapy of differentiated thyroid cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Stunning and I-123 Use for Diagnostic Whole Body ScanningThyroid®, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?Clinical Endocrinology, 2004
- Approximate Is Better than "Exact" for Interval Estimation of Binomial ProportionsThe American Statistician, 1998
- Two-sided confidence intervals for the single proportion: comparison of seven methodsStatistics in Medicine, 1998
- Stunned Thyroid After a Diagnostic Dose of 1-131 for a Whole Body ScanClinical Nuclear Medicine, 1998
- Stunned Thyroid after High-dose 1–131 ImagingClinical Nuclear Medicine, 1992